
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    To annotate the cell type from the provided ranked marker list, we will follow the outlined steps:<br><br>### Step 1: List the Key Functional Markers<br>- **ERBB2 (HER2)**: A receptor tyrosine kinase involved in the growth and differentiation of cells. Overexpression is commonly associated with certain types of breast cancer.<br>- **CALML5**: Calmodulin-like protein involved in calcium signaling pathways.<br>- **CNTNAP2**: A member of the neurexin family, involved in cell adhesion and communication.<br>- **AQP5**: Aquaporin 5, a water channel protein, often associated with glandular tissues.<br>- **CEACAM6**: A cell adhesion molecule, often overexpressed in various cancers.<br>- **DUSP6**: A dual-specificity phosphatase involved in MAPK signaling regulation.<br>- **FADS2**: Fatty acid desaturase, involved in lipid metabolism.<br>- **PSMB3**: A proteasome subunit, part of the protein degradation pathway.<br>- **SOCS7**: A suppressor of cytokine signaling, involved in negative regulation of cytokine signaling.<br>- **GRB7**: An adaptor protein involved in signal transduction pathways, often co-amplified with ERBB2 in breast cancer.<br>- **S100A9**: A calcium-binding protein involved in inflammatory processes.<br>- **CXCL17**: A chemokine involved in immune cell recruitment.<br><br>### Step 2: List the Key Cell Type Markers<br>- **MUCL1**: Mucin-like protein 1, highly expressed in breast tissue and breast cancer.<br>- **SCGB2A2 (Mammaglobin)**: A secretoglobin family member, highly specific to mammary tissue and breast cancer.<br>- **KRT10**: Keratin 10, typically expressed in epithelial cells.<br>- **IGHG1, IGHM, IGKC, IGLC2**: Immunoglobulin genes, indicating the presence of B cells or plasma cells.<br>- **SCD**: Stearoyl-CoA desaturase, involved in lipid biosynthesis, often upregulated in cancer cells.<br>- **SQLE**: Squalene epoxidase, involved in cholesterol biosynthesis, often upregulated in cancer.<br>- **CRIP1**: Cysteine-rich protein, associated with epithelial cells and cancer.<br><br>### Step 3: Cross-reference Known Databases<br>Using databases such as the Human Protein Atlas, CellMarker, and literature on breast cancer, we can cross-reference these markers. MUCL1, SCGB2A2, and ERBB2 are strongly associated with breast epithelial cells, particularly in the context of breast cancer.<br><br>### Step 4: Determine the Most Probable General Cell Type<br>Based on the expression of MUCL1, SCGB2A2, and ERBB2, the most probable general cell type is **breast epithelial cells**, specifically those associated with breast cancer.<br><br>### Step 5: Identify the Top 3 Most Probable Sub Cell Types<br>1. **HER2-positive Breast Cancer Cells**: High expression of ERBB2 (HER2) suggests this subtype.<br>2. **Luminal Epithelial Cells**: Expression of SCGB2A2 and MUCL1 is indicative of luminal epithelial cells in the breast.<br>3. **Basal-like Breast Cancer Cells**: Presence of markers like KRT10 and S100A9 can also suggest a basal-like phenotype, although less likely given the prominence of luminal markers.<br><br>The most likely subtype based on the markers is **HER2-positive Breast Cancer Cells** due to the high expression of ERBB2 and co-expression of GRB7.<br><br>### Step 6: Provide a Concise Summary of Your Analysis<br>The analysis of the ranked marker list from the breast cancer tissue dataset suggests that the cell cluster is most likely composed of breast epithelial cells, specifically HER2-positive breast cancer cells. This conclusion is supported by the high expression of ERBB2, along with other markers like MUCL1 and SCGB2A2, which are characteristic of breast tissue and breast cancer.<br><br>FINAL ANNOTATION COMPLETED
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    Validation result: VALIDATION PASSED<br><br>The proposed annotation result is consistent with the provided marker list and the identified cell type. Here's the breakdown:<br><br>1. **Marker Consistency**: <br>   - The key functional markers and cell type markers listed in the annotation are present in the provided marker list. <br>   - The markers ERBB2, MUCL1, SCGB2A2, and GRB7 are all associated with breast epithelial cells and breast cancer, particularly HER2-positive breast cancer cells, which aligns with the annotation.<br><br>2. **Mixed Cell Type Consideration**:<br>   - The annotation considers the possibility of mixed cell types by identifying potential subtypes such as HER2-positive breast cancer cells, luminal epithelial cells, and basal-like breast cancer cells.<br>   - The presence of markers like KRT10 and S100A9 suggests a potential basal-like phenotype, but the annotation correctly prioritizes the HER2-positive subtype due to the prominence of ERBB2 and associated markers.<br><br>Overall, the annotation is well-supported by the marker list and the analysis provided. The conclusion that the cell cluster is most likely composed of HER2-positive breast cancer cells is justified based on the high expression of relevant markers.
                </div>
            
                        <div class="agent-section formatting">
                            <h2>üìã Summary</h2>
                            
                        <div class="summary-content">
                            <div class="summary-item">
                                <span class="summary-label">Main Cell Type:</span>
                                <span class="summary-value">breast epithelial cells</span>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Sub Cell Types:</span>
                                <ul class="summary-list">
                                    <li>HER2-positive Breast Cancer Cells</li><li>Luminal Epithelial Cells</li><li>Basal-like Breast Cancer Cells</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Possible Mixed Cell Types:</span>
                                <ul class="summary-list">
                                    <li class="empty-list">No mixed cell types identified</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Number of Markers:</span>
                                <span class="summary-value">50</span>
                            </div>
                        </div>
                    
                        </div>
                    
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">90</div>
                        <div class="scoring-content">
                            The annotation results provided demonstrate a strong understanding of the marker list and its implications for identifying cell types within the context of human breast cancer. The analysis correctly identifies key markers such as ERBB2, MUCL1, and SCGB2A2, which are highly relevant to breast epithelial cells and HER2-positive breast cancer. The annotation process is thorough, considering both functional and cell type-specific markers, and cross-referencing with known databases to validate the findings.<br><br>Strengths:<br>1. **Correctness of Annotations**: The identification of HER2-positive breast cancer cells as the primary subtype is well-supported by the presence of ERBB2 and GRB7, both of which are critical markers for this subtype. The inclusion of luminal epithelial cells and basal-like breast cancer cells as potential subtypes shows a comprehensive approach to the analysis.<br>   <br>2. **Balanced Consideration of Markers**: The annotation does not overly focus on a single marker but instead considers a range of markers, including those related to cell adhesion (CEACAM6), signaling pathways (DUSP6, SOCS7), and immune response (S100A9, CXCL17). This balanced approach ensures a more accurate representation of the cell population.<br><br>3. **Comprehensive View**: The analysis captures the general picture of the cell populations by considering both the primary and potential subtypes. The acknowledgment of mixed cell types, although not prominent in the final annotation, indicates an awareness of the complexity of tumor microenvironments.<br><br>Weaknesses:<br>1. **Marker Ranking Consideration**: While the annotation is thorough, it could have placed more emphasis on the ranking of markers. For instance, MUCL1 and SCGB2A2 appear early in the list, suggesting their importance, which is acknowledged but could be further emphasized in the context of luminal epithelial cells.<br><br>2. **Potential Oversights**: The presence of immunoglobulin genes (IGHG1, IGHM, IGKC, IGLC2) suggests a possible involvement of immune cells, such as B cells or plasma cells, which is not fully explored in the annotation. This could indicate a mixed cell population that includes immune components, which might be relevant in the context of tumor microenvironments.<br><br>Overall, the annotation is scientifically accurate and provides a well-rounded view of the cell types present, with minor areas for improvement in marker ranking consideration and potential mixed cell type exploration.<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    